🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

RecruitingPhase 3Ages 18 Years - anyAllSun Yat-sen University
NCT06669611 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

We expect to conduct a clinical trial in recurrent and metastatic nasopharyngeal carcinoma patients to explore and compare the efficacy and safety of induction chemotherapy (TPC vs. GP) with combination therapy of Camrelizumab.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age over 18 years. 2. ECOG score of 0-1. 3. Expected survival of at least 12 weeks. 4. Recurrent/Metastatic Nasopharyngeal Carcinoma. 5. At least 4 weeks since the previous chemotherapy. 6. At least one (according to RECIST) measurable lesion, lesions that have been previously irradiated can not be considered target lesions. 7. had adequate organ function
💊

What it tests

  • Camrelizumab combined GP chemotherapy
  • Camrelizumab combined TPC chemotherapy
📍

Where

1 site
SunYat-senU
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy